Stoke Therapeutics (STOK) said Wednesday it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for zorevunersen as treatment for Dravet syndrome with a confirmed mutation in the SCN1A gene.
Phase 1/2a and open-label extension studies of zorevunersen showed "substantial and sustained reductions in seizure frequency" and improvements in cognitive and behavioral measures, the company said.
Stoke Therapeutics said it is in talks with the FDA and other regulatory bodies about advancing to a global, randomized, controlled phase 3 study and that it will provide an update on the phase 3 registrational plans by year-end.
Stoke Therapeutics shares were up over 10% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.